Post Profile






FDA grants priority review to Roche's Lucentis for mCNV

ZURICH (Reuters) - The U.S. Food and Drug Administration has granted priority review for Roche drug Lucentis for treating myopic choroidal neovascularization (mCNV), the Swiss drugmaker said on Tuesday.
read more

share
See more about: Drug Administration

Related Posts


Probuphine® Receives FDA Priority Review Designation For Adult Patients With Opioid Dependence

Health : Medical News Today

Titan Pharmaceuticals, Inc. (OTCBB:TTNP) have announced that the New Drug Application (NDA) for Probuphine® has been accepted for review and granted Priority Review designation by the U.S. Food and Drug Administration (FDA). Probuph...

Roche say cancer drug Alecensa gets breakthrough therapy designation

Health : Reuters: Health

ZURICH (Reuters) - Roche said on Tuesday its lung cancer drug Alecensa (alectinib), developed by its Genentech unit, received a second breakthrough therapy designation (BTD) from the U.S. Food and Drug Administration (FDA) for its a...

Roche says US approves Avastin drug to treat cervical cancer

News : Yahoo! News: The Upshot

ZURICH (Reuters) - Swiss drugmaker Roche said on Friday the U.S. Food and Drug Administration (FDA) had approved the use of its Avastin cancer drug in combination with chemotherapy to treat advanced cervical cancer. Avastin has now ...

FDA Grants Priority Review For MediQuest's Drug Application To Treat Raynaud's Disease

Health : Medical News Today

MediQuest Therapeutics Inc. announced that it has been granted priority review status from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for MQX-503, a topical formulation designed to treat Raynaud's...

Roche says U.S. FDA issues Emergency Use Authorization for Zika test

Health : Reuters: Health

ZURICH (Reuters) - Swiss drugmaker Roche said on Monday the U.S. Food and Drug Administration (FDA) had issued an Emergency Use Authorization (EUA) for its test for the Zika virus.

Comments


Copyright © 2016 Regator, LLC